Company intelligence / Profile preview

123Genetix

Ownership: Private
Development stage: Preclinical

Overview

123Genetix has developed the DeepNEU platform, a computational simulation technology for rare disease modeling and drug discovery. The platform uses artificial intelligence and machine learning to create simulated stem cell models that can be used for hypothesis generation, experimental planning, and biomarker discovery[1][3].

Therapeutic areas: Rare Diseases
Modalities: Computational modelsSimulated stem cell models
Industry: Academic Hospital/University/Research

Beyond the preview

Go deeper on 123Genetix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 123Genetix.

Explore the full profile